Table 3. Autoantibodies and complement factors in the 13 cases never positive for ANA in the incident Southeast Norway SLE cohort during 2000–2017 (N=737).
| Anti-dsDNA | Case | Anti-ENA | Anti-PL | Low complement | |||||
| Anti-SSA | Anti-SSB | Anti-Sm | Anti-CL | LA | Anti-ß2 GPI | C3 | C4 | ||
| 1 | – | –* | – | – | – | – | – | – | – |
| 2 | + | + | + | – | + | – | – | + | + |
| 3 | – | – | – | – | – | + | – | – | – |
| 4 | + | – | – | + | + | + | + | + | + |
| 5 | – | + | – | – | – | – | – | – | – |
| 6 | – | – | – | – | – | – | – | + | – |
| 7 | – | – | – | – | + | + | + | – | – |
| 8 | – | + | – | – | – | – | – | – | – |
| 9 | – | – | – | – | – | + | – | + | – |
| 10 | – | – | – | – | – | – | – | – | – |
| 11 | – | – | – | – | – | – | – | – | – |
| 12 | – | – | – | – | – | – | – | – | – |
| 13 | – | – | – | – | – | – | – | – | – |
*
cCase 1 has positive anti-ENA, but negative anti-SSA/SSB.
aCL, anti-cardiolipin; aCL, anti-cardiolipin; ANA, antinuclear antibodies; anti-ß2 GPIanti-beta2glycoprotein Ianti-PL, anti-phospholipid; C3, C3 proteins; C4, C4 proteinsdsDNA, double-stranded DNA; ENA, extractable nuclear antigen; LA, lupus anticoagulantPLphospholipidSSA, Sjögren’s-syndrome-related antigen ASSB, Sjögren’s-syndrome-related antigen B